Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · 10x Genomics, Inc. (TXG)

10x Genomics Q2 revenue falls to $151.0M, swings to loss; raises 2026 guidance

Mixed Impact 4 of 5 earnings Written later

10x Genomics reported second quarter 2026 revenue of $151.0 million, down from $172.9 million a year earlier, and a net loss of $17.9 million, compared with net income of $34.5 million in the prior-year quarter. The prior-year period included $27.3 million of patent settlement revenue, and excluding settlement revenue in both periods, revenue rose 3%. The company raised its full-year 2026 revenue guidance to $610 million to $630 million, which shareholders will weigh against the weaker reported quarter.

Key points

  • Q2 2026 revenue was $151.0 million versus $172.9 million in Q2 2025; excluding settlement revenue, revenue rose 3%.
  • Operating loss was $19.6 million versus operating income of $30.1 million a year earlier; net loss was $17.9 million versus net income of $34.5 million.
  • 2026 revenue guidance raised to $610 million to $630 million from $600 million to $625 million.
  • Cash and cash equivalents and marketable securities totaled $552.0 million as of June 30, 2026.

The filing

Company10x Genomics, Inc. (TXG)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:03 PM ET
Accession number0001628280-26-054273

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.